Clonal evolution in chronic lymphocytic leukemia is scant in relapsed but accelerated in refractory cases after chemo(immune) therapy
Marc Zapatka,
Eugen Tausch,
Selcen Öztürk,
Deyan Yordanov Yosifov,
Martina Seiffert,
Thorsten Zenz,
Christof Schneider,
Johannes Blöhdorn,
Hartmut Döhner,
Daniel Mertens,
Peter Lichter,
Stephan Stilgenbauer
Affiliations
Marc Zapatka
Division of Molecular Genetics, German Cancer Research Center, Heidelberg, 69120, Germany
Eugen Tausch
Department of Internal Medicine III, Ulm University Hospital Ulm, 89081, Germany
Selcen Öztürk
Division of Molecular Genetics, German Cancer Research Center, Heidelberg, 69120, Germany
Deyan Yordanov Yosifov
Department of Internal Medicine III, Ulm University Hospital Ulm, 89081, Germany; Mechanisms of Leukemogenesis, German Cancer Research Center (DKFZ), Heidelberg, 69120, Germany
Martina Seiffert
Division of Molecular Genetics, German Cancer Research Center, Heidelberg, 69120, Germany
Thorsten Zenz
University Hospital and University of Zürich, 8091, Switzerland
Christof Schneider
Department of Internal Medicine III, Ulm University Hospital Ulm, 89081, Germany
Johannes Blöhdorn
Department of Internal Medicine III, Ulm University Hospital Ulm, 89081, Germany
Hartmut Döhner
Department of Internal Medicine III, Ulm University Hospital Ulm, 89081, Germany
Daniel Mertens
Department of Internal Medicine III, Ulm University Hospital Ulm, 89081, Germany; Mechanisms of Leukemogenesis, German Cancer Research Center (DKFZ), Heidelberg, 69120, Germany
Peter Lichter
Division of Molecular Genetics, German Cancer Research Center, Heidelberg, 69120, Germany
Stephan Stilgenbauer
Department of Internal Medicine III, Ulm University Hospital Ulm, 89081, Germany
Clonal evolution is involved in the progression of chronic lymphocytic leukemia (CLL). In order to link evolutionary patterns to different disease courses, we performed a long-term longitudinal mutation profiling study of CLL patients. Tracking somatic mutations and their changes in allele frequency over time and assessing the underlying cancer cell fraction revealed highly distinct evolutionary patterns. Surprisingly, in long-term stable disease and in relapse after long-lasting clinical response to treatment, clonal shifts are minor. In contrast, in refractory disease major clonal shifts occur although there is little impact on leukemia cell counts. As this striking pattern in refractory cases is not linked to a strong contribution of known CLL driver genes, the evolution is mostly driven by treatment-induced selection of sub-clones, underlining the need for novel, non-genotoxic treatment regimens.